Ground-breaking cancer treatment
APOMAB® is AusHealth’s flagship project, and in partnership with Telix Pharmaceuticals, aims to revolutionise chemotherapy treatment in cancer patients.
In a traditional case, a patient will undergo chemotherapy treatment to kill cancer cells without ultimately knowing if the treatment has worked.
The APOMAB® technology utilises the discovery that dead or dying cancer cells targeted by chemotherapy express a unique surface molecule which can be targeted by the APOMAB® antibody.
The technology enables radio therapy to be delivered to the cancer cells directly and allows imaging of the cancers.
This means treatment can be delivered with greater efficiency and accuracy.
AusHealth has supported the development of the APOMAB® technology since 2015. and a collaboration and technology licensing agreement is in place between AusHealth and Telix Pharmaceuticals for the treatment of ovarian and lung cancers.
APOMAB® is currently in the clinical trial stage, assessing the effectiveness of the drug in cancer patients.